Glycogene Knock-in Service

Principle of Glycogene Knock-in

Gene knock-in is a technology that introduces or replaces exogenous functional genes into a specific genome site and obtains stable cell expression. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated nuclease 9 (Cas9)-mediated gene knock-in activates the repair mechanism by breaking the DNA double-strand, mainly non-homologous end-joining (NHEJ) and homology-directed repair (HDR). Although homology-directed repair has a low probability of occurring under natural circumstances, in the presence of an exogenous DNA template, donor DNA or concurrently cleaved donor DNA is inserted into the double-strand DNA break (DSB) site through HDR or non-HDR mechanisms, then mediates the precise knock-in of the exogenous gene. Glycogene knock-in has a wide range of applications in the research fields of gene function, disease modeling, drug screening, etc. It aids the study of glycosylation expression mechanisms and allows the development of glycomics to go further.

The strategy for establishing the knock-in cells.Fig.1 The strategy for establishing the knock-in cells. (Kentaro, et al., 2016)

Glycogene Knock-in Service at CD BioGlyco

At CD BioGlyco, our technologies for glycogene knock-in include efficient and scalable epitope labeling using Cas9 ribonucleoproteins and CRISPR/Cas9-mediated knock-in in cell lines. Our services include designing single guide RNA (sgRNA) according to the target gene sequence, and sgRNA cloned into the desired vector. Then, we recombinant plasmid and homologous recombination repair template transfection into the target cell, resistance screening. Lastly, combine with cell genomic polymerase chain reaction (PCR) detection and sequencing to determine whether the gene insertion is correct. Detect the expression and function of glycoprotein through a variety of biological methods. Based on the CRISPR/Cas9 system, we have developed HDR, single-strand annealing (SSA), NHEJ, microhomology-mediated end joining (MMEJ) or homology-mediated end joining (HMEJ) methods, combining these experimental schemes to customize the glycogen knock-in protocol for you. At the same time, we also provide different Technologies for Glycogene Editing and Glycogene Engineering Services, comprehensively helping your development in glycogenomics.

Knock-in cell line process.Fig.2 Knock-in cell line process. (CD BioGlyco)

Applications

  • Glycogene knock-in is used in directed glycogen gene replacement.
  • Glycogene knock-in establishes a glycogene expression model for disease research.
  • Correcting mutations by precise knock-in is used to develop therapeutic targets for inherited single-gene diseases.
  • CRISPR/Cas9 is a helpful tool to evaluate the intrinsic promoter activities for genes.

Advantages of Us

  • We have a first-class Glycogenomics Platform to increase the efficiency of gene integration without the need for any ex vivo chemical modification.
  • We have simplified and optimized our methods to erase the potential off-target risks caused by promoter activity and catalytic activity of the integrase.

CD BioGlyco has always adhered to the client-centric principle and developed a set of Strategies for Glycogene Editing. Moreover, we also provide precise Glycogene Knockout, KnockdownTagging, and Overexpression Services. We have already many experiences and won unanimous praise from clients. If you are interested in our service, please feel free to contact us.

References:

  1. Oh-hashi, K.; et al. Application of NanoLuc to monitor the intrinsic promoter activity of GRP78 using the CRISPR/Cas9 system. Genes to Cells. 2016, 21(10): 1137-1143.
  2. Smirnikhina, S.A.; et al. Ways of improving precise knock-in by genome-editing technologies. Human Genetics. 2019, 138(1): 1-19.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.